The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 20)
Improved Neuromodulation Approaches, 2014
Currently deep brain stimulation (DBS) is limited to "open-loop" stimulation, without real-time adjustment to the patient's state of activity, fluctuations and types of motor symptoms, medication dosages or neural markers of the disease. Changes to DBS settings only occur during clinical appointments or within small ranges by the patient at home. These limitations may contribute to...
Researchers: Helen Brontë-Stewart, MD, MSE
Biosample and Tissue Resource, 2013
Mutations in the glucocerebrosidase (GBA) gene are the most common genetic risk factor for Parkinson's disease (PD). These mutations are present in approximately seven percent of PD patients. The aim of this project is to determine whether the GBA protein (coded by the GBA gene) is altered in the majority brains of sporadic (cause unknown) PD patients without these...
LRRK2 Cohort Consortium, 2012
Parkinson's Institute LRRK2 Cohort: Clinical Phenotype, Pre/Non-Motor and Environmental Risk Assessment
The objective of this award is to better understand the clinical symptoms of patients that carry the most common genetic risk factor for PD the LRRK2 G2019S variant and what role this mutation plays in individuals that were exposed to environmental toxicants.
A novel feature of this work is the investigation of the effect of a second significant genetic cause of Parkinson's dise...
Researchers: Birgitt Schuele, MD, Dr. med.
Rapid Response Innovation Awards, 2012
Orthostatic hypotension is a sudden drop in blood pressure (BP) when an individual changes position. Individuals with Parkinson's disease (PD) commonly suffer from orthostatic hypotension and low BP due to reduced levels of the neurotransmitter norepinephrine. Medications used to treat PD (such as levodopa) reduce norepinephrine levels, thus further reducing BP. Tyrosine is a ...
Researchers: Joanne DiFrancisco-Donoghue, PhD, RCEP
LRRK2 Cohort Working Group, 2012
Two groups have reported a possible association between carrying a LRRK2 mutation and non-skin cancers. In order to determine whether this finding is present in a larger group, or whether specific factors in those populations account for the higher rate of cancer, a larger study from more locations, and with a larger group of Parkinson's subjects and their family...
Researchers: Rachel Saunders-Pullman, MD, MPH, MS